Αρχική World News New hormone treatment for advanced prostate cancer made available in England

New hormone treatment for advanced prostate cancer made available in England

Prostate cancer cells viewed under a microscope.Prostate cancer cells viewed under a microscope.

Men with advanced, hormone-sensitive prostate cancer will now have another treatment option in England, following the approval of the hormone therapy enzalutamide (Xtandi).

The National Institute of Health and Care Excellence (NICE) has approved the combination of enzalutamide and androgen deprivation therapy (ADT) for adults with hormone-sensitive prostate cancer that’s spread to other parts of the body (metastatic prostate cancer).

Kruti Shrotri, Cancer Research UK’s head of policy, said the decision was “good news” for those who could benefit from this treatment.

Patients and clinicians told NICE that people with this type of prostate cancer have limited treatment options and would welcome the option of treatment with enzalutamide. This is especially positive for people who cannot have chemotherapy or choose not to have it due to its potential impact on quality of life.”

New options needed

Right now, people with hormone-sensitive prostate cancer that’s spread are treated with either ADT alone or in combination with chemotherapy and steroids.

But some people choose not to have chemotherapy. According to the NICE appraisal, around 2 in 3 people with hormone-sensitive metastatic prostate cancer take ADT alone – either because they’re not fit enough to take chemotherapy or choose not to because of the potential side effects.

Patient experts explained to the NICE committee that people may have no or few symptoms when they’re first diagnosed with metastatic prostate cancer. And some feel that chemotherapy treatment has too big an impact on their quality of life and may choose to take ADT alone, even though the long-term outcomes may be worse.

Clinical and patient experts agreed that new options – like enzalutamide – are needed.

Enzalutamide blocks testosterone from reaching prostate cancer cells, slowing cancer growth. Combining enzalutamide with ADT is a better tolerated treatment than chemotherapy and ADT. And clinical trial results show that it’s more effective than ADT alone, making it a useful alternative.

Enzalutamide is also an oral therapy, so is more convenient to take than the chemotherapy docetaxel, which is administered intravenously.

Improving progression free survival

Two large clinical trials have looked at the effectiveness of enzalutamide and ADT for treating hormone-sensitive prostate cancer that’s spread to other parts of the body.

People taking enzalutamide plus ADT lived without their cancer growing significantly compared with those taking docetaxel plus ADT. But whether the treatment improves survival overall is unclear based on current data

Despite this uncertainty, the treatment was considered cost-effective for use in the NHS by NICE and will now be an option on the NHS in England. NICE decisions are usually adopted in Wales and Northern Ireland as well, so the decision is likely to affect patients in all 3 nations. Scotland has a separate process for reviewing drugs.

More on this topic

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Foodie Friday: It’s Berry Season!

July is National Berry Month! If berries aren’t part of your daily diet, now is the perfect time to start eating more of these...

No Link Between Viral Vector in Zynteglo and Acute Myeloid Leukaemia

On 23 July 2021, the European Medicines Agency (EMA) announced that its Committee for Medicinal Products for Human Use (CHMP) has endorsed findings of...

Expecting Mom Finds Pregnant Stray Cat And Gives Her A Home

A woman was 9 months pregnant when she found a pregnant stray cat. Unable to bear the thought of the fellow mom giving birth...

3 Questions Cancer Caregivers Can Ask Themselves to Help Prevent Burnout

Karen Warner Schueler is the president of her own executive coaching firm and author of The Sudden Caregiver: A Roadmap for Resilient Caregiving. For...

FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL

July 29, 2021, by NCI Staff FDA's approval of Rylaze is expected to help address a long-running shortage of the drug Erwinia asparaginase for kids...

EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib

On 22 July 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...